SAN RAMON, CA and LOS ALTOS, CA--(Marketwire - October 08, 2012) - Nextrials, Inc., a leader in clinical research software and services, today announced a partnership with InClin, a specialized clinical research organization (CRO) conducting Phase 1-4 studies for the pharmaceutical, biotechnology and medical device industries. With this partnership, researchers can take full advantage of each company's strengths by linking Nextrials' Prism®, an award winning clinical trial data management platform, with InClin's personalized, high-quality services to accelerate study starts and significantly lower drug development costs.
"Our companies have similar approaches to research, particularly when it comes to offering exceptional clinical trial performance and service," said Dirk Thye, MD, CEO of InClin. "We take pride in our ability to deliver superior data quality to our sponsors, and Nextrials' Prism meets our high standards as an enabling data management platform that can significantly shorten the length of time it takes to initiate and monitor a clinical trial. Together, we can help sponsors attain high quality data and potentially expedite the path to approval."
Prism, its design tools and its new iPad interface give pharmaceutical and biotech researchers anytime/anywhere access to key data points, reports and statistics about ongoing studies, regardless of location. It enables sponsors to better manage investigator site data, logistics and costs, including access to real-time data related to patient demographics, recruitment/enrollment status, queries and more.
"As clinical trials become more complex, partnerships such as this one remove some of the organizational and integration headaches from study initiation and monitoring," said James Rogers, CEO and co-founder of Nextrials. "Prism's capabilities, combined with InClin's senior project management team and its standardized performance indicators and quality metrics processes, give sponsors an edge in obtaining critical study data on a timely basis and keeping studies on track."
Nextrials' award-winning Prism melds sophisticated clinical trial management functionality with EDC in a single, integrated package. By receiving a constant flow of data, Prism enables sponsors and sites to fully utilize real-time integration of disparate information and data sources, such as a hospital's EHR or patient records, to better provide high quality care for patients enrolled in clinical trials. This accelerates the time to market for new drugs and devices, improving trial safety and monitoring and substantially lowering development costs. Prism has been globally deployed in North and South America, Europe, Asia, Africa and Australia.
Established in 1998 and based in the San Francisco area, InClin is a premier clinical research organization (CRO) providing Phase 1-4 clinical research services to the pharmaceutical, biotechnology and medical device industries in North America, Europe and Asia. With broad multidisciplinary training, its senior management team members average more than 15 years of clinical research experience and have successfully completed more than 50 pivotal Phase 2 and Phase 3 studies. For more information, please visit www.inclin.com or call 650-961-3422.
Founded by pharmaceutical researchers in 1999, Nextrials offers today's most novel products and services for speeding the delivery of life-saving drugs and medical devices to market. Prism®, its award-winning Electronic Data Capture (EDC) solution, has been used at over 1,500 research sites to streamline the initiation and management of clinical trials. Nextrials has achieved the status of Registered Solutions Provider with the Clinical Data Interchange Standards Consortium (CDISC). The company is headquartered in the San Francisco Bay area. For more information, visit www.nextrials.com or call 925-355-3000.